SOURCE: Rx Safes, Inc.

Rx Safes, Inc.

January 11, 2016 08:30 ET

Rx Safes CEO Lorraine Yarde Interviewed by

Discusses Unauthorized Conversion, Attendance at JP Morgan Healthcare Conference and Sales and Revenue Plans for 2016

HENDERSON, NV--(Marketwired - Jan 11, 2016) - Rx Safes, Inc. (OTCQB: RXSF), the developer of autonomous fingerprint healthcare security products announced today that its CEO Lorraine Yarde, has been featured in an interview update by leading Investor Relations Portal

In light of the recent announcement of an unauthorized debt conversion, Ms. Yarde provides further clarification on the Company's position on the unscrupulous activities of the fund in question. Ms. Yarde also provides an update on the progress of the Company's retail pharmacy relationship, her attendance at the JP Morgan Healthcare Conference, the impetus for revenue growth in 2016 and a clue into an upcoming announcement of an new agreement relating to the Company's Intellectual Property and also her acquisition plans for the coming year.

Ms. Yarde's interview can be heard in its entirety at

"We are hard and fast in our commitment to protect the Company and its shareholders against unscrupulous investment practices. I believe in full public transparency and hence my desire to provide additional information on the situation," stated Ms. Yarde. "At the same time we cannot lose sight of our sales and business development efforts and to that end, I wanted to reinforce our revenue expectations for 2016 as well our commitment to establishing strategic relationships with long-term equity based investment groups, hence my attendance at the JP Morgan Healthcare Conference," Ms. Yarde added.

After completing a significant rebranding and restructuring effort, the Company is poised to commercialize a number of its fingerprint secured medical security products this coming year, into both the professional and consumer healthcare markets. The Company is single handedly leading the way in the development of medical devices and products that provide better security and safety for the storage and delivery of controlled substances. Drug diversion and prescription drug abuse carries a $600 billion annual price tag in the US and the Company's products address this economic burden directly while simultaneously reducing liability for healthcare facilities, preventing loss and improving patient safety.

For information and pricing on the Company's products, please contact Rx Safes, Inc. by email at, by telephone at 1-844 RX SAFES Ext:1, or visit the company's website at

About Rx Safes, Inc.

Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit

Forward-Looking Statements for RXSF:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Contact Information